Opportunity Information: Apply for PA 18 709
This funding opportunity, titled "Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42) - Clinical Trial Not Allowed" (Funding Opportunity Number PA 18 709), is an NIH grant program aimed specifically at small businesses that can build new research-enabling tools for neuroscience and mental health science. It sits in the NIH small business grant mechanisms (R41/R42, which align with SBIR/STTR-style phased development), and it is administered under the National Institutes of Health with a focus aligned to the National Institute of Mental Health (NIMH). The central idea is not to fund clinical testing in humans, but to fund technology development that makes it easier for the broader research community to study and control a particularly important class of brain targets: G-protein coupled receptors (GPCRs).
The scientific focus is on brain-localized GPCRs and on the kinds of technologies that can reveal how these receptors work in real biological contexts, where their structure and function can change over time. GPCRs are major signaling proteins involved in neurotransmission and neuromodulation, and many psychiatric medications act on GPCRs either directly or indirectly. Because mental health conditions are often linked to altered signaling dynamics, receptor localization, receptor conformations, and circuit-level effects, NIMH is signaling interest in tools that do more than just measure whether a receptor is present. The program emphasizes technologies and approaches that help researchers understand and manipulate the dynamic structure and/or function of these receptors in the brain, meaning tools that can capture receptor states, signaling pathways, receptor interactions, trafficking, ligand bias, temporal changes, or context-specific activation in relevant neural systems.
A second major objective is the development of approaches that could enable identification of better chemical probes or candidate therapeutics for these receptors, specifically ligands that are selective and specific. The opportunity explicitly mentions the potential to identify novel agonists, antagonists, or allosteric modulators for GPCR subtypes. In practical terms, that points to platforms and assays that can discover, screen, or validate compounds with improved subtype selectivity, functional selectivity (biased agonism), or allosteric modulation, which is often a route to greater specificity and fewer side effects. The emphasis on "selective and specific" suggests the funder is looking for methods that reduce the common problem of off-target activity across the large GPCR family, especially when targets are closely related.
NIMH also makes clear that the program is open to technologies targeting both well-characterized receptor subtypes and understudied or orphan GPCRs. That matters because many GPCRs expressed in brain remain poorly understood, with unknown endogenous ligands or unclear roles in neural circuits. By explicitly welcoming orphan and understudied receptors, the announcement encourages small businesses to tackle higher-risk, potentially higher-reward targets, as long as the proposed technology or approach plausibly advances the ability to interrogate receptor biology relevant to mental health function or dysfunction. This can include enabling tools that de-risk discovery by providing better receptor expression systems, more physiologically relevant assay formats, better readouts of signaling, or structural and computational approaches that help connect receptor conformation to function.
From an applicant eligibility standpoint, the opportunity is limited to small businesses. Foreign institutions that are non-U.S. entities are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply as components. However, the notice indicates that "foreign components," as defined under the NIH Grants Policy Statement, may be allowed in certain cases. In NIH terms, that generally means a U.S. small business could potentially include a limited, well-justified element of work performed outside the U.S. if it meets NIH policy requirements and is clearly necessary for the project, but the applicant organization itself must be an eligible U.S. small business and the core of the project is expected to be led and managed from the U.S.
Administratively, this is a discretionary grant program under the health funding activity category (CFDA 93.242). The original closing date listed in the source data is 2021-09-05, and the opportunity record was created on 2018-03-15. The source information provided does not specify an award ceiling or the expected number of awards, which typically means applicants would need to consult the full funding announcement and NIH budget guidelines for the relevant small business mechanism to understand allowable budgets, phase structure expectations, and project period limits.
Overall, the opportunity is best understood as a call for enabling technologies rather than a call for conducting clinical trials or delivering a near-term therapeutic. The funder is looking for tool-building and platform development that helps the field study GPCRs in the brain with greater precision and realism, and that can open up new paths to discovering or characterizing receptor modulators relevant to mental health. The common thread is practical impact on research capabilities: methods that allow clearer mechanistic insight into GPCR signaling in neural systems and that help bridge the gap between receptor biology and mental health-related function or dysfunction, without moving into clinical trial activity under this particular announcement.Apply for PA 18 709
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42)-Clinical Trial Not Allowed" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
- This funding opportunity was created on 2018-03-15.
- Applicants must submit their applications by 2021-09-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42) - Clinical Trial Not Allowed (PA 18 709)
1) What is this funding opportunity?
This is an NIH small business funding opportunity titled "Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R41/R42) - Clinical Trial Not Allowed" (Funding Opportunity Number PA 18 709). It supports small businesses developing new research-enabling tools for neuroscience and mental health science, with a specific focus on brain-derived G-protein coupled receptors (GPCRs).
2) Which NIH institute is this opportunity aligned with?
The opportunity is administered under the National Institutes of Health (NIH) and is aligned with priorities of the National Institute of Mental Health (NIMH), based on the stated mental health research focus and emphasis areas.
3) Who can apply?
Eligibility is limited to small businesses. The applicant organization must be an eligible U.S. small business under NIH small business mechanisms (R41/R42).
4) Are non-U.S. (foreign) organizations eligible to apply?
No. Foreign institutions that are non-U.S. entities are not eligible to apply under this opportunity.
5) Can a U.S. small business include a non-U.S. component in the project?
Non-U.S. components of U.S. organizations are not eligible to participate as components. However, "foreign components" (as defined by the NIH Grants Policy Statement) may be allowed in certain cases. In practical terms, that means a limited and well-justified portion of work outside the U.S. may be possible if it meets NIH policy requirements and is clearly necessary, while the applicant remains an eligible U.S. small business and the project is led and managed from the U.S.
6) What grant mechanisms are used in this opportunity?
This opportunity uses the NIH R41/R42 mechanisms, which align with SBIR/STTR-style phased development for small business technology development.
7) What is the main goal of the program?
The central goal is to fund technology development that enables the broader research community to better study and control brain-localized GPCRs in mental health research contexts. The emphasis is on building tools and platforms that increase precision and realism when interrogating GPCR biology in the brain.
8) Are clinical trials allowed under this announcement?
No. This funding opportunity explicitly states "Clinical Trial Not Allowed." It is intended for tool-building and platform development rather than clinical testing in humans.
9) What scientific targets are emphasized?
The scientific focus is on brain-localized GPCRs. These receptors are major signaling proteins involved in neurotransmission and neuromodulation, and many psychiatric medications act on GPCRs directly or indirectly.
10) What kinds of tools or technologies are encouraged?
The opportunity emphasizes technologies that help researchers understand and manipulate the dynamic structure and/or function of brain GPCRs in real biological contexts. Examples of encouraged capabilities include tools that can capture receptor states, signaling pathways, receptor interactions, trafficking, ligand bias, temporal changes, or context-specific activation in relevant neural systems.
11) Does the program focus only on measuring whether a receptor is present?
No. NIMH signals interest in tools that go beyond presence/absence measures and instead help reveal dynamic receptor biology, such as changing receptor conformations, localization, signaling dynamics, and circuit-level effects.
12) Is there an emphasis on receptor dynamics and context?
Yes. A key theme is that GPCR structure and function can change over time and across biological contexts. The program highlights tools that can resolve temporally changing states, context-specific activation, and other dynamic features of GPCR signaling in neural systems.
13) Does this opportunity support discovery of chemical probes or potential therapeutics?
It supports approaches that enable identification of better chemical probes or candidate therapeutics for brain GPCRs, especially ligands that are selective and specific. The intent is to fund platforms and assays that make it easier to discover, screen, or validate improved modulators of GPCR function.
14) What types of GPCR ligands are explicitly mentioned?
The opportunity explicitly mentions the potential to identify novel agonists, antagonists, or allosteric modulators for GPCR subtypes.
15) What does "selective and specific" mean in this context?
Based on the description, "selective and specific" points to methods designed to reduce off-target activity across the large GPCR family, particularly when targets are closely related. This includes improving subtype selectivity, functional selectivity (biased agonism), and allosteric modulation as routes to greater specificity and fewer side effects.
16) Are orphan or understudied GPCRs within scope?
Yes. The opportunity is open to technologies targeting well-characterized GPCR subtypes as well as understudied or orphan GPCRs, including receptors with unknown endogenous ligands or unclear roles in neural circuits.
17) Does the program encourage higher-risk targets?
It welcomes orphan and understudied receptors, which often implies higher-risk, potentially higher-reward work, as long as the proposed technology plausibly advances the ability to interrogate receptor biology relevant to mental health function or dysfunction.
18) What kinds of approaches might help "de-risk" discovery for orphan/understudied receptors?
The description points to enabling tools that could de-risk discovery by providing better receptor expression systems, more physiologically relevant assay formats, improved signaling readouts, or structural and computational approaches that connect receptor conformation to function.
19) Is this intended to fund a near-term therapeutic program?
The opportunity is best understood as a call for enabling technologies rather than a call to deliver a near-term therapeutic. It focuses on tool-building and platform development that expands research capabilities, without moving into clinical trial activity under this announcement.
20) What is the funding activity category and CFDA number?
The funding activity category is health, and the CFDA number listed is 93.242.
21) What is the funding opportunity number (FON)?
The Funding Opportunity Number is PA 18 709.
22) When was this opportunity record created?
The opportunity record was created on 2018-03-15.
23) What is the closing date listed in the provided information?
The original closing date listed in the provided information is 2021-09-05.
24) Does the provided information include an award ceiling or expected number of awards?
No. The provided source information does not specify an award ceiling or the expected number of awards.
25) Where would an applicant typically look for budget and project period details?
Because the provided information does not include budget ceilings, expected award counts, or detailed limits, applicants would typically consult the full funding announcement and NIH budget guidelines associated with the R41/R42 small business mechanisms to understand allowable budgets, phase expectations, and project period limits.
26) What is the practical impact NIMH appears to be seeking?
The common thread is practical impact on research capabilities: tools and methods that allow clearer mechanistic insight into GPCR signaling in neural systems and that help bridge receptor biology to mental health-related function or dysfunction, while staying within non-clinical trial activities.
Browse more opportunities from the same category: Health
Next opportunity: Science and Technology Policy Fellowships Program
Previous opportunity: Understanding the Effects of ApoE2 on the Interaction between Aging and Alzheimers Disease (R01 - Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 18 709
Applicants also applied for:
Applicants who have applied for this opportunity (PA 18 709) also looked into and applied for these:
| Funding Opportunity |
|---|
| Genomic Centers for Infectious Diseases (U19 Clinical Trial Not Allowed) Apply for RFA AI 18 004 Funding Number: RFA AI 18 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R01 Clinical Trial Not Allowed) Apply for PAR 18 712 Funding Number: PAR 18 712 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Novel Tools for Investigating Brain-derived GPCRs in Mental Health Research (R43/R44 Clinical Trial Not Allowed) Apply for PA 18 708 Funding Number: PA 18 708 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Sexually Transmitted Infections (STI) Cooperative Research Centers (CRC): Vaccine Development (U19 Clinical Trial Not Allowed) Apply for RFA AI 18 005 Funding Number: RFA AI 18 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Request for Information: USAID/DRC’s WASH Planning Apply for 72066018RFI01 Funding Number: 72066018RFI01 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| NIA Limited Competition: Renewals of, and Revisions to, Existing Alzheimer's Disease Patient Registry Cooperative Agreement Awards (U01 - Clinical Trial Not Allowed) Apply for PAR 18 715 Funding Number: PAR 18 715 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| International Bioethics Research Training Program (D43 Clinical Trial Optional) Apply for PAR 18 716 Funding Number: PAR 18 716 Agency: National Institutes of Health Category: Health Funding Amount: $230,000 |
| Generating New insights and Mechanistic Understanding of Antibiotic Resistance Development (R01 Clinical Trial Not Allowed) Apply for PA 18 725 Funding Number: PA 18 725 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NEI Institutional Mentored Physician Scientist Award (K12 Clinical Trial Optional) Apply for PAR 18 726 Funding Number: PAR 18 726 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21 Clinical Trial Not Allowed) Apply for PAR 18 721 Funding Number: PAR 18 721 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R21 Clinical Trial Not Allowed) Apply for PA 18 724 Funding Number: PA 18 724 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R21 Clinical Trial Not Allowed) Apply for PA 18 718 Funding Number: PA 18 718 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Accelerating Basic and Translational Research in Hidradenitis Suppurativa (R01 Clinical Trial Not Allowed) Apply for PA 18 719 Funding Number: PA 18 719 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Investigator-Initiated Genomic Medicine Research (R01 Clinical Trial Optional) Apply for PAR 18 735 Funding Number: PAR 18 735 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Investigator-Initiated Genomic Medicine Research (R21 Clinical Trial Optional) Apply for PAR 18 736 Funding Number: PAR 18 736 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) Apply for PAR 18 737 Funding Number: PAR 18 737 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed) Apply for RFA RM 18 011 Funding Number: RFA RM 18 011 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Limited Competition: Building Infrastructure Leading to Diversity (BUILD) Initiative Phase II (U54 Clinical Trial Not Allowed) Apply for RFA RM 18 006 Funding Number: RFA RM 18 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) Apply for RFA AR 19 007 Funding Number: RFA AR 19 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) Apply for RFA AR 19 006 Funding Number: RFA AR 19 006 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 18 709", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.